·   姓名:许岳慷

·   职称:教授

·   电话:0553-3869080

·   邮箱:yuekang.xu@hotmail.com

◆主要学习工作经历

…………………………………………………………

·   1985年安徽医科大学获医学学士

·   1987年安徽师范大学获文学学士

·   2004年澳大利亚墨尔本大学获哲学博士

·   1987--1998在安徽医科大学工作

·   1998--2014在澳大利亚墨尔本大学工作

·   2014--至今在安徽师范大学工作

◆主要社会兼职

…………………………………………………………

·   安徽省细胞生物学学会常务理事

·   安徽省免疫学会理事

·   澳大利亚免疫协会会员

◆主要研究内容

…………………………………………………………

·   免疫细胞的信号传导:当外界病原微生物侵入机体时,免疫细胞首先做出反应。本实验室主要研究免疫细胞在受到炎性刺激后,胞内信号通路中哪些分子发生了变化,这些变化最终如何改变免疫细胞功能和行为,以及根据这些变化找到并合成该分子的类似物或拮抗剂以控制炎性信号的发展,从而达到临床治疗的目的。

·   树突状细胞的发育:树突状细胞在免疫反应中起着支配和主导作用。不同的生长因子和生长环境控制产生不同的树突状细胞。本实验室主要研究在树突状细胞的发育过程中哪些因素通过什么方式控制产生了什么类型的树突状细胞,这些树突状细胞功能上有什么区别,能主导着什么样的免疫反应,以及我们能否利用这些因素在体外定向生产这种树突状细胞回输体内干预免疫反应。

·   免疫生化:树突状细胞不仅调节免疫应答而且大量产生胱抑素C。胱抑素C是一种蛋白酶抑制剂,控制着组织基质内蛋白溶酶的活性。同时它也是一种纤维化蛋白,可在血管内形成纤维沉淀而破坏血管内壁。本实验室主要研究哪些因素可以调节胱抑素C的分泌,哪些因素会诱导胱抑素C纤维化的形成及分泌,以及这些因素是否可以被用于临床来治疗因蛋白溶酶活性过高、过低或胱抑素C纤维化而导致的疾病(如动脉粥样硬化和阿茲海默症等)

◆主要研究课题

…………………………………………………………

·   国家自然科学基金重大研究计划项目、血管组织DC的区域免疫特性及抑炎机制、91742101、国家基金委、2018/01-2020/12、主持。

·   安徽省对外科学技术合作项目、炎症条件下树突状细胞发育和功能的分子机制研究、1604b0602017、安徽省科技厅、2016/01-2018/12、主持。

·   安徽省自然基金面上项目、胱抑素C调控在血管内膜损伤机制中的研究、1608085MH160、安徽省自然科学基金委员会、2016/07-2018/06、主持。

◆主要研究成果

…………………………………………………………

1、代表性论文(20篇以内,*号为通讯作者):

·   Li X, Ding Y, Zi M, Sun L, Zhang W, Chen S, Xu Y*. CD19, from bench to bedside. Immunol Lett. 183:86-95. 2017

·   Xu, Y*, Ding, Y., Li, X., and Wu, X. Cystatin C is a disease-associated protein subject to multiple regulation. Immunol Cell Biol. 93(5):442-51.2015

·   Xu Y*, Lindemann P, Vega-Ramos J, Zhang JG, Villadangos JA. Developmental Regulation of Synthesis and Dimerization of the Amyloidogenic Protease inhibitor Cystatin C in the Hematopoietic System.

·   J Biol Chem. 289(14):9730-40. 2014. 

·   Xu Y*, Fairfax K, Light A, Huntington ND, Tarlinton DM. CD19 Differentially Regulates BCR Signalling through the Recruitment of PI3K. Autoimmunity. 2014 Jun 23:1-8. [Epub ahead of print].

·   Xu W, Pan H, Xu Y*, and Ye D. Interferon Regulatory Factor 5 and Autoimmune Lupus. Expert Rev Mol Med. 10.1017/erm2013.7. 2013.  (*senior author)

·   Li B, Ye Q, Xu W, Li J, Ye D and Xu Y*. GM-CSF alters dendritic cells in autoimmune diseases. Autoimmunity. 46:409. 2013. 

·   Zhan Y, Vega-Ramos J, Carrington EM, Villadangos JA, Lew AM and Xu Y*. The inflammatory cytokine, GM-CSF, alters the developmental outcome of murine dendritic cells. Eur J Immunol. 42:2889. 2012.

·   Xu WD. Pan HF, Ye DQ, and Xu Y*. Targeting IRF4 in autoimmune diseases. Autoimmun. Rev. 11:918. 2012.

·   Xu Y, Huntington ND, Harder K, Nandurkar H, Hibbs ML and Tarlinton. Phosphatidylinositol-3 kinase activity in B cells is negatively regulated by Lyn tyrosine kinase. Immunol Cell Biol. 90:903. 2012

·   Xu Y*, Schnorrer P, Proietto A, Kowalski G, Febbraio MA, Acha-Orbea  H, Dickins RA and Villadangos JA. Interleukin-10 Controls Cystatin C Synthesis and Blood Concentration in Response to Inflammation through Regulation of IRF-8 Expression.  J. Immunol. 186:3666 (2011).

·   Zhan Y, Xu Y, Seah S, Brady JL, Carrington EM, Cheers C, Croker BA, Wu L, Villadangos JA, Lew AM. Resident and monocyte-derived dendritic cells become dominant IL-12 producer under different conditions and signaling pathways. J. Immunol. 185(4):2125-33 (2010).

·   Xu Y*, Zhan Y, Lew AM, Naik SH and Kershaw MH.   Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking. J. Immunol 179(11):7577-84 (2007).

·   Xu Y, Darcy PK, and Kershaw MH.  Tumor-specific dendritic cells generated by genetic redirection of Toll-like receptor signaling against the tumor-associated antigen, erbB2. Cancer Gene Ther. 14(9):773-80 (2007).

·   Huntington ND, Xu Y, Puthalakath H, Light A, Willis SN, Strasser A, Tarlinton DM.  CD45 links the B cell receptor with cell survival and is required for the persistence of germinal centers.  Nat. Immunol. 7(2):190-8. (2006).

·   Xu Y, Harder KW, Huntington ND, Hibbs ML, and Tarlinton DM.  Lyn tyrosine kinaseaccentuating the positive and the negative. Immunity. 22:9-18 (2005).

·   Huntington ND, Xu Y, Nutt S, Tarlinton DM.  A requirement for CD45 distinguishes Ly49D-mediated cytokine and chemokine production from killing in primary NK cells.  J. Exp. Med. 201:1421-33 (2005).

·   Xu Y, Davies J, Ramsland P, Holmdahl R, Kumar N, Scealy M, Rowley M. Two monoclonal antibodies to precisely the same epitope of type II collagen select non-crossreactive phage clones by phage displayimplications for autoimmunity and molecular mimicry. Mol. Immunol. 41:411-9 (2004).

·   Enders A, Bouillet P, Puthalakath H, Xu Y, Tarlinton DM, Strasser A.   Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. J Exp. Med. 198:1119-26 (2003).

·   Xu Y, Beavitt SJ, Harder KW, Hibbs ML, Tarlinton DM.  The activation and subsequent regulatory roles of Lyn and CD19 after B cell receptor ligation are independent.  J. Immunol.  169:6910-8 (2002).

2、主要获奖情况(省部级以上):

·   2014:安徽省“百人计划”入选专家 安徽省“特聘教授”。中国,安徽。

·   2013ICB Publications of the Year Runner Up Awards, Australia

·   2011-2013NHMRC Project Grant (APP1006428, CIA), Australia.

·   2010International Postdoctoral Travel Award from Australian Society of Immunology, Australia.

·   2008International Travel Bursary from 4th Congress of the Federation of Immunology Societies of Asia-Oceania (FIMSA).

·   2008International Travel Award from Australian Society of Immunology.

·   2006-2010NHMRC Peter Doherty Fellowship, Australia.

·   2006-2009Susan Komen Postdoctoral Fellowship, Susan Komen Foundation, USA.